<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362777">
  <stage>Registered</stage>
  <submitdate>20/07/2012</submitdate>
  <approvaldate>23/07/2012</approvaldate>
  <actrnumber>ACTRN12612000778886</actrnumber>
  <trial_identification>
    <studytitle>Nebulised frusemide to imporve the sensation and unpleasant feeling of dyspnoea in patients with advanced diseases and breathlessness refractory to optimal standard management</studytitle>
    <scientifictitle>Nebulised frusemide to improve the sensation and unpleasant feeling of dyspnoea in patients with advanced diseases and breathlessness refractory to optimal standard management</scientifictitle>
    <utrn>U1111-1132-7746</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dyspnoea in advanced diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>20mg-40mg of nebulised frusemide, i.e. one or two 20mg/2ml Sandoz ampoules without the addition of saline, delivered by a jet nebuliser. Dosage is determined clinically based on patient's concomitant disease status thus tolerability. The treatment can be given concurrently with pre-existing oxygen on the same rate (Litres/min). Each session of treatment will last no longer than 10 minutes.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change of the sensation of dyspnoea measured by a Modified BORG scale</outcome>
      <timepoint>30 minutes and 60 minutes after the initiation of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change of the unpleasant feeling of dyspnoea measured by the anxiety section of a Hospital Anxiety and Depression Scale</outcome>
      <timepoint>At the end of each day during a 2 day treatment schedule</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Primary diagnosis of any irreversible disease. Prognosis of the disease needs to be less than 12 months. 
-Refractory dyspnoea that is not reponsive to more establisehd therapies.
-Any concomitant disease but not rapidly deteriorating
-Willingness to give informed consent documented by the treating team and willingness to participate and comply with the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-Unwilling/unable to give informed consent
-Unable to tolerate frusemide 
-Rapid deterioration
-Hepatic encephalopathy
-Anuric renal failure
-Mental or cognitive disorder, unable to reliably self-report or consent
-Significant hypotension with the risk of further pronounced drop in blood pressure
-Currently receiving risperidone
-Significant history of gout
-Significant change in medication that may affect dyspnoea within the last 24 hours
-Hypersensitivity to frusemide or any inactive ingredient
-Actively receiving treatment for dyspnoea, for example pleural effusion drainage or blood transfusion
-Electrolyte disturbance
-Aversion/inability to fit mask</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation is not concealed.</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2050</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Maria Cristina Cigolini</primarysponsorname>
    <primarysponsoraddress>Department of Palliative Care, Royal Prince Alfred Hospital, Missenden Road
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Prince Alfred Hospital</sponsorname>
      <sponsoraddress>Missenden Road
Camperdown NSW 2050</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trials is a open label case series study in which we will investigate the effect of nebulised frusemide on patients with advanced diseases and dyspnoea, refractory to current therapeutic modalities. We will administer 20-40mg of frusemide via a jet nebuliser twice daily over a 2 day period. Patients' levels of the sensation of breathlessness and the unpleasant feeling elicited will be measured by a modified BORG scale and HADS-A subscale.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SLHD Ethics Review Committee (RPAH Zone)</ethicname>
      <ethicaddress>Mailing Address:
c/- Research Development Office
Royal Prince Alfred Hospital
Missenden Road
CAMPERDOWN NSW 2050 

Delivery Address:
Research Development Office
RPAH Medical Centre
Suite 210A, 100 Carillon Avenue
NEWTOWN NSW 2042</ethicaddress>
      <ethicapprovaldate />
      <hrec>X12-0193 &amp; HREC/12/RPAH/309</hrec>
      <ethicsubmitdate>8/06/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Maria Cristina Cigolini</name>
      <address>Gloucester House 2, Department of Palliative medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, 2050 NSW</address>
      <phone>+61 2 95157755</phone>
      <fax>+61 2 95157464</fax>
      <email>maria.cigolini@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Maria Cristina Cigolini</name>
      <address>Gloucester House 2, Department of Palliative medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, 2050 NSW</address>
      <phone>+61 2 95157755</phone>
      <fax>+61 2 95157464</fax>
      <email>maria.cigolini@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Maria Cristina Cigolini</name>
      <address>Gloucester House 2, Department of Palliative medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, 2050 NSW</address>
      <phone>+61 2 95157755</phone>
      <fax>+61 2 95157464</fax>
      <email>maria.cigolini@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>